Stealth BioTherapeutics has begun the Phase I/II CHALLENGE-HD clinical trial of SBT-20 in the Netherlands to treat patients with early stage Huntington’s disease.

SBT-20 is an investigational tetrapeptide currently being developed to improve mitochondrial function for slowing down the neuronal degeneration and disease progression.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two-part, randomised, double-blind, placebo-controlled Phase I/II trial is currently being conducted at the Centre for Human Drug Research (CHDR) and is designed to assess the safety, tolerability and efficacy of various doses of daily subcutaneous SBT-20 in adult patients.

The trial will enrol a total of 24 patients who will participate in both parts of the trial.

Stealth BioTherapeutics chief executive officer Reenie McCarthy said: “The initiation of CHALLENGE-HD is a significant milestone for Stealth as our second drug candidate enters human trials in a new therapeutic area.

“We plan to use the results from this trial to better inform our SBT-20 pipeline development plan and the broader potential of our platform in neurodegenerative disorders.”

“As a leader in mitochondrial medicine, we want to pursue the full potential of mitochondria-targeted therapies, in rare primary mitochondrial diseases, common diseases of ageing and now in neurodegenerative disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We plan to use the results from this trial to better inform our SBT-20 pipeline development plan and the broader potential of our platform in neurodegenerative disorders.”

The first part of the trial will include administration of one of three ascending doses of 5mg, 15mg and 25mg SBT-20 for seven days.

The data from this part of the trial will be used to choose a dose for administration in the second part for 28 days.

The primary endpoints of the trial are safety and tolerability, while the secondary endpoints include a measure of SBT-20’s effect on mitochondrial, motor function and pharmacokinetic profile.